Efficacy of Dabrafenib Plus Trametinib in First-Line Treatment for Children and Adolescents with Low-Grade Glioma with BRAF V600 Mutations
Findings from the phase II study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
A Combination of Amivantamab and Lazertinib Shows Durable Clinical Activity in the Osimertinib-Relapsed EGFR-mutated Advanced NSCLC Setting
Findings from the cohort E of CHRYSALIS study
A Combination of Tucatinib and Trastuzumab Demonstrates Activity and Favourable Tolerability in Patients with Previously Treated HER2-positive Metastatic Biliary Tract Cancer
Findings from the BTC cohort of SGNTUC-019 study
EMA Recommends Extending Indications for Pembrolizumab to Include Adjuvant Treatment in NSCLC
It is intended as monotherapy for the adjuvant treatment of adults with non-small cell lung cancer who are at high risk of recurrence following complete resection and platinum-based chemotherapy
Axicabtagene Ciloleucel Results in High Response Rates and Durable Remissions as a Second-Line Treatment for Patients with Relapsed or Refractory Large B Cell Lymphoma Ineligible for ASCT
Findings from the ALYCANTE study
An Alternative Model for Genetic Testing Delivery Proposed with Posttest Counselling for Those with Pathogenic Variants and On Demand for Those Without Pathogenic Variants
Findings from the MAGENTA study
FDA Approves New and Updated Indications for Temozolomide Under Project Renewal
Project Renewal is limited to updating labelling information for older oncology drugs to ensure information is clinically meaningful and scientifically up-to-date
EMA Recommends Granting a Marketing Authorisation for Quizartinib
It is intended for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML
Efficacy and Safety of Patritumab Deruxtecan in Patients with EGFR-mutated NSCLC that Progressed to EGFR TKI and Platinum-Based Chemotherapy
Findings from the HERTHENA-Lung01 study
A Combination of Oral Mezigdomide Plus Dexamethasone Shows Promising Efficacy in Patients with Heavily Pretreated Multiple Myeloma
Findings from the CC-92480-MM-001 study
Trastuzumab Deruxtecan Demonstrates Durable Responses in Patients with Previously Treated HER2-mutated Metastatic NSCLC
Primary results from DESTINY-Lung02 study
FDA Grants Accelerated Approval to Elranatamab-bcmm for Multiple Myeloma
Evidence for efficacy is based on the results from the MagnetisMM-3 study